The outcome of a national MS-Covid-19 study: What the Turkish MS cohort reveals?
dc.contributor.buuauthor | Turan, Ömer Faruk | |
dc.contributor.department | Uludağ Üniversitesi/ Tıp Fakültesi/Dahili Tıp Bilimleri/Nöroloji Anabilim Dalı | tr_TR |
dc.contributor.researcherid | JDI-6091-2023 | tr_TR |
dc.contributor.scopusid | 23037113500 | tr_TR |
dc.date.accessioned | 2024-01-19T07:48:08Z | |
dc.date.available | 2024-01-19T07:48:08Z | |
dc.date.issued | 2021-07 | |
dc.description | Çalışmada 24 yazar bulunmaktadır. Bu yazarlardan sadece Bursa Uludağ Üniversitesi mensuplarının girişleri yapılmıştır. | |
dc.description.abstract | Background: The pandemic of the new type of corona virus infection 2019 [Covid-19] also affect people with Multiple Sclerosis (pwMS). Currently, the accumulating information on the effects of the infection regarding the & nbsp;& nbsp;demographic and clinical characteristics of the disease, as well as outcomes within different DMTs & cedil; enable us to have better practices on the management of the Covid-19 infection in pwMS. Objective: To investigate the incidence of coronavirus disease 2019 (Covid-19) and to reveal the relationship between the demographic-clinical and therapeutic features and the outcome of Covid-19 infection in a multi- center national cohort of pwMS.& nbsp; Methods: The Turkish Neurological Society-MS Study Group in association with the Italian MuSC-19 Study Group initiated this study. A web-based electronic Case Report Form (eCRF) of Study-MuSC-19 were used to collect the data. The demographic data and MS histories of the patients were obtained from the file tracking forms of the relevant clinics.& nbsp; Results: 309 MS patients with confirmed Covid-19 infection were included in this study. Two hundred nineteen (219) were females (70.9%). The mean age was 36.9, ranging from 18 to 66, 194 of them (62.8%) were under 40. The clinical phenotype was relapsing-remitting in 277 (89.6%) and progressive in 32 (10.4%). Disease duration ranged from 0.2 years to 31.4 years. The median EDSS was 1.5, ranging from 0 to 8.5. The EDSS score was<= 1 in 134 (43%) of the patients. 91.6% of the patients were on a DMT, Fingolimod was the most frequently used drug (22.0%), followed by Interferon (20.1%). The comorbidity rate is 11.7%. We were not able to detect any significant association of DMTs with Covid-19 severity.& nbsp; Conclusion: The Turkish MS-Covid-19 cohort had confirmed that pwMS are not at risk of having a more severe COVID-19 outcome irrespective of the DMT that they are treated. In addition, due to being a younger population with less comorbidities most had a mild disease further highlight that the only associated risk factors for having a moderate to severe COVID-19 course are similar with the general population such as having comorbid conditions and being older. | en_US |
dc.identifier.citation | Turan, Ö. F. vd. (2021). "The outcome of a national MS-Covid-19 study: What the Turkish MS cohort reveals?". Multiple Sclerosis and Related Disorders, 52. | en_US |
dc.identifier.doi | https://doi.org/10.1016/j.msard.2021.102968 | |
dc.identifier.issn | 2211-0348 | |
dc.identifier.issn | 2211-0356 | |
dc.identifier.pubmed | 33940495 | tr_TR |
dc.identifier.scopus | 2-s2.0-85104941699 | tr_TR |
dc.identifier.uri | https://www.sciencedirect.com/science/article/pii/S2211034821002352 | |
dc.identifier.uri | https://hdl.handle.net/11452/39181 | |
dc.identifier.volume | 52 | tr_TR |
dc.identifier.wos | 000669497800023 | tr_TR |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.wos | SCIE | en_US |
dc.language.iso | en | en_US |
dc.publisher | Elsevier SCI LTD | en_US |
dc.relation.collaboration | Yurt içi | |
dc.relation.collaboration | Sanayi | |
dc.relation.collaboration | Yurt dışı | |
dc.relation.journal | Multiple Sclerosis and Related Disorders | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Multiple Sclerosis | en_US |
dc.subject | Coronavirus | en_US |
dc.subject | Disease modifying treatment | en_US |
dc.subject | Disease severity | en_US |
dc.subject | Rituximab | en_US |
dc.subject.emtree | Alemtuzumab | en_US |
dc.subject.emtree | Dimethyl fumarate | en_US |
dc.subject.emtree | Fingolimod | en_US |
dc.subject.emtree | Glatiramer | en_US |
dc.subject.emtree | Interferon | en_US |
dc.subject.emtree | Methylprednisolone | en_US |
dc.subject.emtree | Natalizumab | en_US |
dc.subject.emtree | Ocrelizumab | en_US |
dc.subject.emtree | Rituximab | en_US |
dc.subject.emtree | Teriflunomide | en_US |
dc.subject.emtree | Fingolimod | en_US |
dc.subject.emtree | Adult | en_US |
dc.subject.emtree | Aged | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | Clinical feature | en_US |
dc.subject.emtree | Clinical outcome | en_US |
dc.subject.emtree | Clinical practice | en_US |
dc.subject.emtree | Cohort analysis | en_US |
dc.subject.emtree | Comorbidity | en_US |
dc.subject.emtree | Controlled study | en_US |
dc.subject.emtree | Coronavirus disease 2019 | en_US |
dc.subject.emtree | Demography | en_US |
dc.subject.emtree | Disease association | en_US |
dc.subject.emtree | Disease duration; | en_US |
dc.subject.emtree | Disease exacerbation | en_US |
dc.subject.emtree | Disease severity | en_US |
dc.subject.emtree | Expanded disability status scale | en_US |
dc.subject.emtree | Female | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | Incidence | en_US |
dc.subject.emtree | Major clinical study | en_US |
dc.subject.emtree | Male | en_US |
dc.subject.emtree | Medical society | en_US |
dc.subject.emtree | Middle aged | en_US |
dc.subject.emtree | Multiple sclerosis | en_US |
dc.subject.emtree | Nasopharyngeal swab | en_US |
dc.subject.emtree | Nose smear | en_US |
dc.subject.emtree | Outcome assessment | en_US |
dc.subject.emtree | Phenotype | en_US |
dc.subject.emtree | Real time polymerase chain reaction | en_US |
dc.subject.emtree | Serology | en_US |
dc.subject.emtree | Turkey (republic) | en_US |
dc.subject.mesh | Adult | en_US |
dc.subject.mesh | Cohort studies | en_US |
dc.subject.mesh | COVID-19 | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Fingolimod hydrochloride | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Multiple sclerosis | en_US |
dc.subject.mesh | SARS-CoV-2 | en_US |
dc.subject.scopus | Natalizumab; Multiple Sclerosis; Fingolimod | en_US |
dc.subject.wos | Clinical Neurology | en_US |
dc.title | The outcome of a national MS-Covid-19 study: What the Turkish MS cohort reveals? | en_US |
dc.type | Article | en_US |
dc.wos.quartile | Q2 | en_US |
Files
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: